Embecta (EMBC) Stock Price, News & Analysis

Company Overview

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and markets medical devices used to deliver insulin and monitor blood glucose. Its product portfolio includes insulin pen needles, insulin syringes, safety-engineered injection devices, lancets and related diabetes-management products.

The company serves people with diabetes, health care professionals, hospitals and other health care providers through commercial operations and distribution partners in markets around the world. Embecta’s products are designed to support diabetes treatment and monitoring across a range of care settings, including home care and clinical environments.

Embecta became an independent publicly traded company in April 2022 after being spun off from Becton, Dickinson and Company, where its business had operated as the Diabetes Care segment. The company is headquartered in Parsippany, New Jersey, and is led by Chief Executive Officer Devdatt Kurdikar.

Key Stats

• Today's Range: $6.21 to $6.52
• 50-Day Range: $4.75 to $6.45
• 52-Week Range: $2.77 to $14.91
• Volume: 746,137 shs
• Average Volume: 1.50 million shs
• Market Capitalization: $363.76 million
• P/E Ratio: 4.34
• Dividend Yield: 0.62%
• Price Target: $11.00
• Consensus Rating: Reduce

Embecta Stock Analysis - MarketRank™

Embecta scored higher than 76% of companies evaluated by MarketBeat, and ranked 155th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Embecta has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Embecta has a consensus price target of $11.00, representing about 72.6% upside from its current price of $6.37.

Amount of Analyst Coverage

Embecta has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -4.35%

Earnings Growth

Earnings for Embecta are expected to decrease by -4.35% in the coming year, from $1.84 to $1.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Embecta is 4.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of Embecta is 4.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.56.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.42% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 5.43.

Change versus previous month

Short interest in Embecta has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Embecta has a dividend yield of 0.64%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Embecta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Embecta is 2.70%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Embecta will have a dividend payout ratio of 2.27% next year. This indicates that Embecta will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Embecta has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Embecta this week, compared to 8 articles on an average week.

Search Interest

1 people have searched for EMBC on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Embecta to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Embecta in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $297,197.00 in company stock, which represents 0.0823% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Embecta insiders have bought 803.17% more of their company's stock than they have sold. Specifically, they have bought $334,200.00 in company stock and sold $37,003.00 in company stock.

Percentage Held by Insiders

1.30% of the stock of Embecta is held by insiders.

Percentage Held by Institutions

93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Record date for 9/15 Dividend: 8/27/2026
• Ex-Dividend for 9/15 Dividend: 8/27/2026
• Dividend Payable: 9/15/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/24/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:EMBC
• CIK: 1872789
• Web: www.embecta.com
• Phone: 201-847-6880
• Fax: N/A
• Employees: 1,850
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Embecta: $11.00
• High Price Target: $25.00
• Low Price Target: $3.00
• Potential Upside/Downside: +71.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.48
• Trailing P/E Ratio: 4.34
• Forward P/E Ratio: 3.49
• P/E Growth: N/A
• Net Income: $95.40 million
• Net Margins: 8.59%
• Pretax Margin: 12.27%
• Return on Equity: -19.25%
• Return on Assets: 10.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.68
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $1.08 billion
• Price / Sales: 0.34
• Cash Flow: $4.09 per share
• Price / Cash Flow: 1.57
• Book Value: ($11.12) per share
• Price / Book: -0.58

Miscellaneous

• Outstanding Shares: 56,660,000
• Free Float: 55,923,000
• Market Cap: $363.76 million
• Optionable: Optionable
• Beta: 0.84